Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.

Image placeholder title

Radius Health (RDUS) - Get Report : For his first exclusive interview, Cramer sat down with Bob Ward, president and CEO of Radius Health, the biotech with shares that have been more than cut in half so far in 2016 as the hostile environment for the industry rages on.

Ward said that his company's treatment for osteoporosis continues to see great results and studies now include 2,400 patients in 20 countries. He noted that while some analysts see limited potential for Radius' treatments, the fact is that more Americans are afflicted with osteoporosis than cancer.

Ward said while millions of patients are suffering from osteoporosis, a full two-thirds of them are never diagnosed or treated for the disease. That's what makes Radius' drugs so exciting.

Beyond osteoporosis, Ward noted trials continue for the rest of Radius' pipeline. He added Radius is not looking to raise more cash at this time.

Cramer said one day good news will matter for Radius, and when it does shares are going higher.

Seres Therapeutics (MCRB) - Get Report : In his second exclusive interview, Cramer also sat down with Dr. Roger Pomerantz, chairman, president and CEO of Seres, the biotech working to help restore balance in your intestinal tract.

Image placeholder title

Pomerantz explained there are trillions of bacteria that live in our intestinal tract, but when patients take antibiotics the natural balance of these bacteria is upset, leading to reinfections and other illnesses. Seres' treatments replace the missing bacteria and restore a natural balance.

Seres aims to meet this huge unmet medical need while also saving the health care system money by lowering hospital re-admittance. The company has partnered with Nestle Health Services to help bring its treatments to patients all over the globe.

Cramer said Seres is yet another example of a great biotech that is being dragged lower by the broader markets.

To read a full recap of "Mad Money" on CNBC, click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.